CN119552111B - 抗血小板药物和其用途 - Google Patents

抗血小板药物和其用途

Info

Publication number
CN119552111B
CN119552111B CN202411716601.2A CN202411716601A CN119552111B CN 119552111 B CN119552111 B CN 119552111B CN 202411716601 A CN202411716601 A CN 202411716601A CN 119552111 B CN119552111 B CN 119552111B
Authority
CN
China
Prior art keywords
mmol
present disclosure
compounds
alkyl
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202411716601.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN119552111A (zh
Inventor
顾自强
张袁超
何公欣
侯凯
吴豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai CureGene Pharmaceutical Co Ltd
Original Assignee
Shanghai CureGene Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai CureGene Pharmaceutical Co Ltd filed Critical Shanghai CureGene Pharmaceutical Co Ltd
Publication of CN119552111A publication Critical patent/CN119552111A/zh
Application granted granted Critical
Publication of CN119552111B publication Critical patent/CN119552111B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CN202411716601.2A 2020-07-29 2021-07-28 抗血小板药物和其用途 Active CN119552111B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof
CN202180058245.8A CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180058245.8A Division CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Publications (2)

Publication Number Publication Date
CN119552111A CN119552111A (zh) 2025-03-04
CN119552111B true CN119552111B (zh) 2026-01-02

Family

ID=80037185

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411716601.2A Active CN119552111B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202410873004.4A Active CN119033782B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202311275197.5A Pending CN117343000A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202180058245.8A Pending CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202410873004.4A Active CN119033782B (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202311275197.5A Pending CN117343000A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途
CN202180058245.8A Pending CN116194459A (zh) 2020-07-29 2021-07-28 抗血小板药物和其用途

Country Status (14)

Country Link
US (2) US12410132B2 (cg-RX-API-DMAC7.html)
EP (2) EP4342532B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906376B1 (cg-RX-API-DMAC7.html)
CN (4) CN119552111B (cg-RX-API-DMAC7.html)
AR (1) AR123078A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021317436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3046366T3 (cg-RX-API-DMAC7.html)
IL (1) IL299979A (cg-RX-API-DMAC7.html)
MX (1) MX2023001232A (cg-RX-API-DMAC7.html)
TW (1) TWI925859B (cg-RX-API-DMAC7.html)
WO (1) WO2022022559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532B (zh) * 2023-06-29 2026-05-15 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN116194459A (zh) 2023-05-30
KR20230047425A (ko) 2023-04-07
IL299979A (en) 2023-03-01
TW202214609A (zh) 2022-04-16
JP7899159B2 (ja) 2026-08-03
CN119033782A (zh) 2024-11-29
TWI925859B (zh) 2026-05-21
KR20250073569A (ko) 2025-05-27
MX2023001232A (es) 2023-05-15
US20250333382A1 (en) 2025-10-30
EP4342532C0 (en) 2025-09-03
US20240279178A1 (en) 2024-08-22
AU2021317436A1 (en) 2023-02-23
ES3046366T3 (en) 2025-12-01
CN119552111A (zh) 2025-03-04
CA3186645A1 (en) 2022-02-03
EP4342532B1 (en) 2025-09-03
EP4188935A1 (en) 2023-06-07
KR102906376B1 (ko) 2025-12-30
AR123078A1 (es) 2022-10-26
WO2022022559A1 (en) 2022-02-03
CN119033782B (zh) 2025-04-25
US12410132B2 (en) 2025-09-09
EP4342532A3 (en) 2024-07-17
EP4188935A4 (en) 2024-07-17
EP4342532A2 (en) 2024-03-27
BR112023001595A2 (pt) 2023-04-04
CN117343000A (zh) 2024-01-05
JP2023535815A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
CN119033782B (zh) 抗血小板药物和其用途
WO2024153119A1 (en) Kras g12d inhibitors and uses thereof
CN115141215B (zh) Kras g12d蛋白抑制剂和其用途
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
CN120882724A (zh) Kras g12d抑制剂和其用途
CN118909031B (zh) 抗冠状病毒化合物及其组合物和用途
JP2020532506A (ja) 化合物、組成物、及び、方法
EP4470539A1 (en) Pharmaceutical composition of antiplatelet drug, and use thereof
AU2021321905A1 (en) ATR inhibitors and uses thereof
KR102797099B1 (ko) 2-[(3r)-3-메틸모르폴린-4-일]-4-(1-메틸-1h-피라졸-5-일)-8-(1h-피라졸-5-일)-1,7-나프티리딘의 제조 방법
US11834413B2 (en) Antiplatelet drugs and uses thereof
RU2841656C1 (ru) Антитромбоцитарные лекарственные средства и их применение
HK40117914A (en) Antiplatelet drugs and uses thereof
HK40117914B (en) Antiplatelet drugs and uses thereof
HK40090099A (en) Antiplatelet drugs and uses thereof
JPH0412273B2 (cg-RX-API-DMAC7.html)
WO2023138621A1 (en) Atr inhibitors and uses thereof
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant